This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.
Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab
That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
$43.5m and a $2.5bn licensing deal with Jounce for five immuno-oncology candidates.
Celgene has bolstered its immuno-oncology pipeline in an agreement with US biotech Jounce Therapeutics that gives it options on five experimental cancer therapies. ... According to Jounce Celgene was one of several companies trying to close a licensing
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
US clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development. ... We are thrilled to welcome him to Jounce at a critical point in our drug development process.”.
Raythatha re-joins the firm from Jounce Therapeutics where he was chief business officer, leading its business strategy and development since December 2012.
pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...